Mirion Enhances Radiopharmaceutical Production with Cutting-Edge Apex-Guard Software
Mirion Enhances Radiopharmaceutical Production with Cutting-Edge Apex-Guard Software Mirion Technologies (NYSE: MIR), a global leader in radiation safety solutions, has announced the latest release of its Apex-Guard gamma spectroscopy software.…
Devonian Announces Delay in Financial Results Release
Devonian Announces Delay in Financial Results Release Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical-stage biopharmaceutical company specializing in the development of innovative therapies…
ENHERTU Phase 3 DESTINY-Gastric05 Trial Starts for Untreated HER2+ Advanced Gastric Cancer
ENHERTU Phase 3 DESTINY-Gastric05 Trial Starts for Untreated HER2+ Advanced Gastric Cancer The first patient has been successfully dosed in the DESTINY-Gastric05 phase 3 trial, which aims to evaluate the…
LucyRx Unveils Bold Brand Identity, Celebrates Key Milestones to Simplify PBM and Enhance Patient Care
LucyRx Unveils Bold Brand Identity, Celebrates Key Milestones to Simplify PBM and Enhance Patient Care LucyRx, a next-generation pharmacy benefit manager (PBM), is shaking up the landscape of prescription care…
Omeros Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results
Omeros Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results Omeros Corporation has announced its recent developments, clinical updates, and financial results for the fourth quarter and full year ended…
Lilly’s RNA Silencer Achieves Nearly 94% Reduction in Key Cardiovascular Biomarker
Lilly’s RNA Silencer Achieves Nearly 94% Reduction in Key Cardiovascular Biomarker Eli Lilly has made a groundbreaking advancement in cardiovascular medicine with its investigational small interfering RNA (siRNA) therapeutic, lepodisiran,…
Sanofi and Alnylam Secure Landmark RNAi Approval for Hemophilia A & B
Sanofi and Alnylam Secure Landmark RNAi Approval for Hemophilia A & B Sanofi and Alnylam have achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval…
European Commission Approves TIVDAK® for Recurrent or Metastatic Cervical Cancer
European Commission Approves TIVDAK® for Recurrent or Metastatic Cervical Cancer Genmab A/S has announced that the European Commission (EC) has officially granted marketing authorization for TIVDAK® (tisotumab vedotin), an antibody-drug…
BeiGene’s TEVIMBRA® Gets CHMP Nod for First-Line Lung Cancer Treatment
BeiGene’s TEVIMBRA® Gets CHMP Nod for First-Line Lung Cancer Treatment BeiGene, Ltd., a global oncology company soon to be rebranded as BeOne Medicines Ltd., has announced a significant milestone in…
WuXi Biologics Achieves ISO 22301 Certification and Expands ISO/IEC 27001 Compliance
WuXi Biologics Achieves ISO 22301 Certification and Expands ISO/IEC 27001 Compliance WuXi Biologics (“WuXi Bio”) (2269.HK), a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a significant…
Ono & Reborna Partner for CNS RNA-Targeting Drug Discovery
Ono & Reborna Partner for CNS RNA-Targeting Drug Discovery Ono Pharmaceutical Co., Ltd. (Headquartered in Osaka, Japan; President and COO: Toichi Takino; hereafter referred to as “Ono”) has announced a…
Guideline Development Group Maternal Peripartum Infection Treatment
Maternal sepsis is a life-threatening condition that arises from an infection during pregnancy, childbirth, post-abortion, or the postpartum period. It is a significant public health challenge and ranks as the…